In the decade since palbociclib (Ibrance) received FDA approval, results from multiple clinical trials have provided a strong evidence base to make cyclin-dependent kinase (CDK)4/6 inhibitors, in ...
Clinicians treating patients with estrogen receptor (ER)-positive/HER2-negative metastatic breast cancer are navigating ...
Sara A. Hurvitz, MD, of UCLA Health spoke with The American Journal of Managed Care® (AJMC®) about advanced hormone receptor–positive (HR+), HER2-negative breast cancer and the emergence of CDK4/6 ...
A leading breast cancer specialist examines the growing role of CDK4/6 inhibitors in the adjuvant treatment of HR+/HER2- early breast cancer, citing the monarchE and NATALEE trials, and explores ...
SAN ANTONIO — For patients with advanced hormone receptor-positive, HER2-negative breast cancer, health-related quality of life is the same whether they receive CDK4/6 inhibitors in the first or ...
This study is carried out by Prof. Qiang Liu (Breast Tumor Center, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University). In this study, researchers found that the palbociclib-resistant breast cancer ...
Camizestrant plus CDK4/6 inhibitors improved progression-free survival in ESR1-mutated, ER-positive, HER2-negative advanced breast cancer compared to AI and CDK4/6 inhibitors. The SERENA-6 trial used ...
SAN ANTONIO — A machine learning model, which incorporates both clinical and genomic factors, helps predict which patients with hormone receptor–positive (HR+)/human epidermal growth factor receptor 2 ...
No significant OS advantage was found among CDK4/6 inhibitors for HR-positive, HER2-negative metastatic breast cancer. Real-world data showed median OS of 54.6 months for Ibrance, 59 months for ...
Ovarian cancer, a leading cause of death among gynecological malignancies, has a poor prognosis and low 5-year survival rate, necessitating new therapeutic strategies. CDK4/6 inhibitors show promise ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback